As Vitrakvi (larotrectinib) becomes the second drug to get FDA approval for a site-agnostic indication, physicians will have yet another reason to order sequencing, said David Hyman, chief of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center and the principal investigator for a larotrectinib clinical trial that led to the approval.
The American Cancer Society’s 2026 annual statistics report trumpets a symbolic milestone for oncology—for the first time, the five-year relative survival rate for all cancers combined has reached 70% for people diagnosed between 2015 and 2021 in the U.S.
